Clinical trials: Obesity or Overweight
Overweight or Obesity
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
The present clinical investigation is a randomized, double-blinded, placebo-controlled, multicenter international trial, planned to be conducted in Poland, Romania and Slovakia.
- Trial name
- SHINE (NCT06087822)
- Testing
- IMD SiPore21®
- Where
- 27 sites in Poland, Romania and 1 more
- Volunteers
- 318 people
- Sponsor
- Sigrid Therapeutics AB
Obesity, Overweight
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2…
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- AMPLIFY-2 (NCT07881458)
- Testing
- eloralintide and tirzepatide, Tirzepatide
- Where
- 75 sites in United States, Brazil and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight, Type 2 Diabetes
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-4 (NCT07843485)
- Testing
- Petrelintide
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.
Overweight and Obesity
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
- Trial name
- EMBRAZE (NCT06445075)
- Testing
- Apitegromab, Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Scholar Rock, Inc.
Obesity, Overweight
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- AMAZE 8 (NCT07400107)
- Testing
- NNC0487-0111, Semaglutide
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorders, Overweight or Obesity
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body.
- Trial name
- NCT03574584
- Testing
- NNC0165-1562, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Obesity, Weight Loss
Obese Patients With or Without Comorbidities (RIO-North America)
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
- Trial name
- NCT00029861
- Testing
- Rimonabant (SR141716)
- Where
- 51 sites in United States, Canada
- Volunteers
- 3,045 people
- Sponsor
- Sanofi
Overweight, Obesity
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy)…
- Trial name
- NCT00444561
- Testing
- pramlintide acetate
- Where
- 10 sites in United States
- Volunteers
- 184 people
- Sponsor
- AstraZeneca
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Obesity, Overweight
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity.
- Trial name
- NCT07597018
- Testing
- Cagrilintide D
- Where
- Germany
- Volunteers
- 234 people
- Sponsor
- Novo Nordisk A/S
Alcohol Use Disorder (AUD)
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight.
- Trial name
- NCT06987513
- Testing
- Pemvidutide
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Altimmune, Inc.
Overweight, Obesity
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
- Trial name
- NCT06910839
- Testing
- PF-07976016, PF-06882961
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.
- Trial name
- NCT00533481
- Testing
- MK0557
- Volunteers
- 497 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other…
- Trial name
- NCT07874633
- Testing
- Berobenatide
- Where
- 2 sites in China
- Volunteers
- 432 people
- Sponsor
- Pfizer
Healthy, Obesity
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or…
- Conditions
- Healthy, Obesity, Overweight
- Trial name
- NCT07407348
- Testing
- Formulation A, Formulation B6
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Overweight
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
This is a two-part, single centre, double-blind (within cohorts), randomised, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men…
- Trial name
- NCT06144684
- Testing
- GUB014295
- Where
- United Kingdom
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- AbbVie
Overweight or Obesity
A Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose of SYH2082 Injection in healthy participants.
- Trial name
- NCT07736404
- Testing
- SYH2082 Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.